BARD1 and breast cancer: In studies of ≥500 cancer cases, the prevalence of potentially pathogenic BARD1 variants ranged from 0.18–0.53% [11,47], 0.67–0.9% [13,22], and 0.07–0.23% [37,63] in BC, TNBC and OC cases, respectively.